GH-2 Double Nickase Plasmid (h): sc-401171-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- GH-2 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- GH-2 Double Nickase Plasmid (h) and GH-2 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting GH2. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
GH-2 Double Nickase Plasmid (h) | sc-401171-NIC | 20 µg | $410.00 | |||
GH-2 Double Nickase Plasmid (h2) | sc-401171-NIC-2 | 20 µg | $410.00 |
Growth hormone 2 (GH2) encodes GH-2, a placental growth hormone variant that engages growth hormone receptor signaling to influence systemic growth-related processes and metabolic homeostasis. GH-2 activity is linked to JAK2/STAT, MAPK/ERK, and PI3K/AKT pathway modulation, integrating endocrine cues with transcriptional programs controlling nutrient utilization and insulin-like growth factor axis regulation. In human biology, altered placental growth hormone dynamics have been associated with dysregulated maternal–fetal growth and metabolic adaptation, making GH2 a relevant locus for mechanistic studies of endocrine signaling. Because GH2 shares sequence and functional overlap with other growth hormone family members, it is also useful for dissecting paralog-specific regulation and receptor engagement in cellular models.
GH-2 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the GH2 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within GH2. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt GH2 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of GH2-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.